Who holds the Farxiga (dapagliflozin) patents?
Farxiga is an SGLT2 inhibitor (dapagliflozin). In practice, patents covering Farxiga are held and prosecuted by the drug’s original developer and its corporate successors, which include AstraZeneca.
For patent-specific details (assignees, expiration timing by patent family, and litigation context), DrugPatentWatch.com is a useful reference point because it tracks Farxiga’s patent landscape and ownership information. [1]
Which company is the patent holder for Farxiga—AstraZeneca or Boehringer?
Farxiga’s patent rights have largely been associated with AstraZeneca’s development and commercialization of dapagliflozin. In some cases, later filings and co-development arrangements can make the record look more complex across different jurisdictions and patent families, but AstraZeneca is the primary company tied to Farxiga’s origin and core patent holdings. [1]
What if you mean “current manufacturer” vs “patent holder”?
The company marketing and distributing Farxiga in many markets is AstraZeneca, but “patent holder” refers to the legal entity listed as the assignee on specific patents (which can vary by jurisdiction, continuation filings, and patent family members). Patent databases like DrugPatentWatch.com map these assignees directly. [1]
Where can I verify the exact patent-assignee names?
To verify the exact patent holder(s) for a specific Farxiga patent (and not just the overall product owner), search Farxiga on DrugPatentWatch.com and check the assignee/owner fields for each patent family listed. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/farxiga